Intravitreal ranibizumab injections used to treat AMD caused a significant change in RNFL thickness after 12 months of follow-up.

No abstract

Monthly intravitreal injection of ranibizumab for 3 months has a short-term beneficial anatomic effect.

Patients in stage II without PED have a better visual and anatomic evolution than patients in stage II with PED and stage III.

Healthy subjects and glaucoma patients differ significantly in terms of mean overall corneal thickness and thicknesses of the corneal zones I to VI defined here. The variables mean corneal thickness and mean thicknesses of zones IV and VI are able to discriminate between subjects with or without glaucoma.